z-logo
open-access-imgOpen Access
Identification of characteristic subepithelial surface granulomatosis in immune‐related adverse event‐associated enterocolitis
Author(s) -
Kubo Terufumi,
Hirohashi Yoshihiko,
Keira Yoshiko,
Akimoto Mayuko,
Ikeda Tatsuru,
Kikuchi Noriaki,
Iwaki Hiroyuki,
Kikuchi Tomoki,
Obata Masahiko,
Morita Rena,
Kasai Kiyoshi,
Segawa Keiko,
Tsukahara Tomohide,
Kanaseki Takayuki,
Murata Kenji,
Kikuchi Yasuhiro,
Shinkawa Tomoyo,
Hasegawa Tadashi,
Torigoe Toshihiko
Publication year - 2021
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.14773
Subject(s) - medicine , ulcerative colitis , colitis , enterocolitis , histopathology , exacerbation , granuloma , immune system , adverse effect , gastroenterology , immunology , pathology , disease
Immune checkpoint inhibitors (ICIs) have provided an additional treatment option for various types of human cancers. However, ICIs often induce various immune‐related adverse events (irAEs). Enterocolitis is a major irAE with poorly understood histopathological characteristics. In this study, we retrospectively investigated the histopathology of colon tissue samples from 17 patients treated with ICIs. There were two major histological patterns of colitis: an ulcerative colitis‐like pattern and a graft vs host disease‐like pattern. Although these two patterns of colitis were mutually exclusive, both patterns often showed a characteristic that we call “subepithelial surface granulomatosis” (SSG), which has not been reported in other types of colitis. SSG was found even in colon tissue without symptoms or endoscopic findings of colitis. Given the increasing reports of sarcoid reaction or exacerbation of tuberculosis after treatment with ICIs, granuloma formation could be a histological hallmark of systemic immune activation by ICIs. Although statistical significance was not obtained, probably because of the small sample size, SSG may be a surrogate biomarker of systemic anticancer immune activation. We propose that a prospective study with larger sample size be performed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here